Peginterferon beta-1a

PLEGRIDY is indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults.

Prescribing label

Selected manufacturer label information, organised into consistent sections by Sofidex. This source is written for healthcare professionals; ask your pharmacist to explain instructions that are unclear. Read the full label at DailyMed ↗

Drug facts

Used for: PLEGRIDY is indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults.
Do not take if: PLEGRIDY is contraindicated in patients with a history of hypersensitivity to natural or recombinant interferon beta or peginterferon, or any other component of PLEGRIDY.

Side effects, and when to stop

The following serious adverse reactions are discussed in more detail in other sections of labeling:

Hepatic Injury
Depression and Suicide
Anaphylaxis and Other Allergic Reactions
Injection Site Reactions Including Necrosis
Congestive Heart Failure
Decreased Peripheral Blood Counts
Thrombotic Microangiopathy
Pulmonary Arterial Hypertension
Autoimmune Disorders
Seizures

Who should not take it

PLEGRIDY is contraindicated in patients with a history of hypersensitivity to natural or recombinant interferon beta or peginterferon, or any other component of PLEGRIDY.

Storing it

Store PLEGRIDY prefilled pens and prefilled syringes in a refrigerator between 2°C to 8°C (36°F to 46°F) in the closed original carton to protect from light until ready for injection. Do not freeze. Discard if frozen.

If refrigeration is unavailable, PLEGRIDY may be stored at room temperature up to 25°C (77°F) for a period up to 30 days, protected from light. PLEGRIDY can be removed from, and returned to, a refrigerator if necessary. The total combined time out of refrigeration should not exceed 30 days.

PLEGRIDY prefilled syringe for intramuscular administration contains natural rubber latex which may cause allergic reactions.

Dispose in a sharps-bin container or other hard plastic or metal sealable container. Always follow local regulations for disposal.

Cite this page

NLM: sofidex [Internet]. Daloreum; c2026. Peginterferon beta-1a; [reviewed 2026 Aug 3; cited 2026 Nov 10]. Available from: https://sofidex.com/patients/medicines/peginterferon-beta-1a
APA 7th: sofidex. (2026, August 3). Peginterferon beta-1a. Daloreum. Retrieved November 10, 2026, from https://sofidex.com/patients/medicines/peginterferon-beta-1a
AMA 11th: Peginterferon beta-1a. sofidex. Reviewed August 3, 2026. Accessed November 10, 2026. https://sofidex.com/patients/medicines/peginterferon-beta-1a

The cited date is today’s, because a citation records when you read the page. The reviewed date is when a clinician last checked it.